Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
10x Genomics (TXG) had Return on Equity of -25.72% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$610.78M |
|
$-182.63M |
|
$196.30M |
|
$414.48M |
|
$805.34M |
|
$-194.56M |
|
$16.86M |
|
$-177.70M |
|
$-177.70M |
|
$-182.63M |
|
$-182.63M |
|
$-182.63M |
|
$-182.63M |
|
$-194.56M |
|
$-150.85M |
|
120.45M |
|
120.45M |
|
$-1.52 |
|
$-1.52 |
|
| Balance Sheet Financials | |
$584.39M |
|
$252.65M |
|
$334.25M |
|
$918.64M |
|
$117.63M |
|
-- |
|
$90.87M |
|
$208.50M |
|
$710.13M |
|
$689.95M |
|
$710.13M |
|
122.29M |
|
| Cash Flow Statement Financials | |
$6.66M |
|
$-32.63M |
|
$10.91M |
|
$359.28M |
|
$344.07M |
|
$-15.22M |
|
$140.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.97 |
|
-- |
|
-- |
|
-- |
|
-- |
|
67.86% |
|
-31.85% |
|
-31.85% |
|
-24.70% |
|
-29.09% |
|
-29.90% |
|
$-5.73M |
|
-- |
|
-- |
|
-- |
|
0.66 |
|
2.36 |
|
6.95 |
|
52.51 |
|
|
Return on Equity |
-25.72% |
-26.47% |
|
-19.88% |
|
-25.72% |
|
$5.81 |
|
$-0.05 |
|
$0.06 |
|